大腸直腸神經內分泌腫瘤的病理診斷

10.6666/ClinMed.201912_84(6).0132

何宜軒；李芬瑤

大腸直腸神經內分泌腫瘤（colorectal neuroendocrine neoplasm） ； 神經內分泌瘤（neuroendocrine tumor, NET） ； 神經內分泌腺癌（neuroendocrine carcinoma, NEC） ； 混合神經內分泌－非神經內分泌贅瘤（mixed neuroendocrine-non-neuroendocrine neoplasm, MiNEN）

臨床醫學月刊

84卷6期（2019 / 12 / 27）

798 - 803

繁體中文

大腸及直腸的神經內分泌腫瘤雖然相較於大腸直腸腺癌，發生率較低，但隨著大腸鏡的普及，發生率近年來有上升的趨勢。關於神經內分泌腫瘤相關的研究，多著墨於肺臟及胰臟這兩個器官，故此篇會詳述有關大腸直腸內分泌腫瘤的流行病學、臨床表現、病理型態、免疫染色、分級及分期、分子病理、治療及預後等的相關進展。

1. Ali, AS,Grönberg, M,Federspiel, B(2017).Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.PLoS One,12,e0187667.
2. Dasari, A,Shen, C,Halperin, D(2017).Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.JAMA Oncol,3,1335-1342.
3. de Herder, WW,Rehfeld, JF,Kidd, M(2016).A short history of neuroendocrinetumours and their peptide hormones.Best Practice & Research Clinical Endocrinology & Metabolism,30,3-17.
4. Ito, T,Igarashi, H,Nakamura, K(2015).Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.J Gastroenterol,50,58-64.
5. Kim, JY,Hong, S-M(2016).Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.Arch Pathol Lab Med,140,437-448.
6. Kloppel, G,Adsay, NV,Couvelard, A(2018).Pancreatic neuroendocrine neoplasms : Introduction.Board WCoTE WHO Classification of Tumours Digestive System Tumours,Lyon, France:
7. Leoncini, E,Boffetta, P,Shafir, M(2017).Increased incidence trend of lowgrade and high-grade neuroendocrine neoplasms.Endocrine,58,368-379.
8. Leoncini, E,Carioli, G,La Vecchia, C(2016).Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis.Ann Oncol,27,68-81.
9. Rindi, G,Komminoth, P,Scoazec, JY(2018).Colorectal neuroendocrine neoplasms.Board WCoTE WHO Classification of Tumours Digestive System Tumours,Lyon,France:
10. Rubin de Celis Ferrari, AC,Glasberg, J,Riechelmann, RP(2018).Carcinoid syndrome: update on the pathophysiology and treatment.Clinics,73,e490s.
11. Starzynska, T,Londzin-Olesik, M,Baldys-Waligorska, A(2017).Colorectal neuroendocrine neoplasms-management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Endokrynol Pol,68,250-260.
12. Takizawa, N,Ohishi, Y,Hirahashi, M(2015).Molecular characteristics ofcolorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor.Hum Pathol,46,1890-1900.
13. Tsai, H-J,Wu, C-C,Tsai, C-R(2013).The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study.PLoS One,8,e62487.
14. Wang, Y,Wang, W,Jin, K(2017).Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrinen eoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.Oncol Lett,13,1165-1174.